Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details) - USD ($) $ in Millions		9 Months Ended	12 Months Ended
	Oct. 15, 2018	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Estimated fair value of tangible assets acquired and liabilities assumed:
Goodwill		$ 268.6	$ 268.6	$ 259.7
Measurement Period Adjustments
Goodwill, measurement period adjustments		8.9
Total purchase price		$ 0.0
Adapt Pharma
Estimated fair value of tangible assets acquired and liabilities assumed:
Cash	$ 17.7
Accounts receivable	21.3
Inventory	41.4
Prepaid expenses and other assets	10.8
Accounts payable	(32.2)
Accrued expenses and other liabilities	(50.4)
Deferred tax liability, net of current	(62.9)
Total fair value of tangible assets acquired and liabilities assumed	(54.3)
Acquired in-process research and development	41.0
Acquired intangible asset	534.0
Goodwill	148.0
Total purchase price	668.7
Measurement Period Adjustments
Prepaid expenses and other assets, measurements period adjustments			3.0
Deferred tax liability, net, measurement period adjustments			(0.5)
Total fair value of tangible assets acquired and liabilities assumed, measurement period adjustments			2.5
Goodwill, measurement period adjustments			(1.0)
Total purchase price	1.5		$ 1.5
Adapt Pharma | Previously Reported
Estimated fair value of tangible assets acquired and liabilities assumed:
Cash	17.7
Accounts receivable	21.3
Inventory	41.4
Prepaid expenses and other assets	7.8
Accounts payable	(32.2)
Accrued expenses and other liabilities	(50.4)
Deferred tax liability, net of current	(62.4)
Total fair value of tangible assets acquired and liabilities assumed	(56.8)
Acquired intangible asset	534.0
Goodwill	149.0
Total purchase price	$ 667.2